Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
Status:
Not yet recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this research is to find out if an aggressive intervention to lose weight,
will improve symptoms in patients with obesity-related cardiomyopathy, which is also known as
the obese phenotype of heart failure with preserved ejection fraction (HFpEF).